367 related articles for article (PubMed ID: 17552518)
1. Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. possible new GSK-3beta therapies for bipolar disorders.
Kozikowski AP; Gaisina IN; Yuan H; Petukhov PA; Blond SY; Fedolak A; Caldarone B; McGonigle P
J Am Chem Soc; 2007 Jul; 129(26):8328-32. PubMed ID: 17552518
[TBL] [Abstract][Full Text] [Related]
2. Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder.
Dandekar MP; Valvassori SS; Dal-Pont GC; Quevedo J
Curr Drug Metab; 2018; 19(8):663-673. PubMed ID: 29283064
[TBL] [Abstract][Full Text] [Related]
3. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
4. Identification of a glycogen synthase kinase-3β inhibitor that attenuates hyperactivity in CLOCK mutant mice.
Kozikowski AP; Gunosewoyo H; Guo S; Gaisina IN; Walter RL; Ketcherside A; McClung CA; Mesecar AD; Caldarone B
ChemMedChem; 2011 Sep; 6(9):1593-602. PubMed ID: 21732538
[TBL] [Abstract][Full Text] [Related]
5. Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection.
Li X; Bijur GN; Jope RS
Bipolar Disord; 2002 Apr; 4(2):137-44. PubMed ID: 12071511
[TBL] [Abstract][Full Text] [Related]
6. Lithium and valproate act on the GSK-3β signaling pathway to reverse manic-like behavior in an animal model of mania induced by ouabain.
Valvassori SS; Dal-Pont GC; Resende WR; Jornada LK; Peterle BR; Machado AG; Farias HR; de Souza CT; Carvalho AF; Quevedo J
Neuropharmacology; 2017 May; 117():447-459. PubMed ID: 27789311
[TBL] [Abstract][Full Text] [Related]
7. Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge.
Rybakowski JK
CNS Drugs; 2013 Mar; 27(3):165-73. PubMed ID: 23378337
[TBL] [Abstract][Full Text] [Related]
8. Lymphocyte Phospho-Ser-9-GSK-3β/Total GSK-3β Protein Levels Ratio Is Not Affected by Chronic Lithium or Valproate Treatment in Euthymic Patients With Bipolar Disorder.
Azab AN; Vainer E; Agam G; Bersudsky Y
J Clin Psychopharmacol; 2017 Apr; 37(2):226-230. PubMed ID: 28106616
[TBL] [Abstract][Full Text] [Related]
9. Glycogen synthase kinase-3beta in the platelets of patients with mood disorders: effect of treatment.
Pandey GN; Ren X; Rizavi HS; Dwivedi Y
J Psychiatr Res; 2010 Feb; 44(3):143-8. PubMed ID: 19717166
[TBL] [Abstract][Full Text] [Related]
10. Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons.
Hall AC; Brennan A; Goold RG; Cleverley K; Lucas FR; Gordon-Weeks PR; Salinas PC
Mol Cell Neurosci; 2002 Jun; 20(2):257-70. PubMed ID: 12093158
[TBL] [Abstract][Full Text] [Related]
11. Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3beta.
Silva R; Mesquita AR; Bessa J; Sousa JC; Sotiropoulos I; Leão P; Almeida OF; Sousa N
Neuroscience; 2008 Mar; 152(3):656-69. PubMed ID: 18291594
[TBL] [Abstract][Full Text] [Related]
12. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3.
Chen G; Huang LD; Jiang YM; Manji HK
J Neurochem; 1999 Mar; 72(3):1327-30. PubMed ID: 10037507
[TBL] [Abstract][Full Text] [Related]
13. [Association between lithium sensitivity and GSK3beta gene polymorphisms in bipolar disorder].
Numajiri M; Aoki J; Iwahashi K; Fukamauchi F; Enomoto M; Yoshihara E; Murayama O; Nishizawa D; Ikeda K; Ishigooka J
Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Jun; 32(3):161-3. PubMed ID: 22834106
[TBL] [Abstract][Full Text] [Related]
14. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
Darshit BS; Balaji B; Rani P; Ramanathan M
J Mol Graph Model; 2014 Sep; 53():31-47. PubMed ID: 25064440
[TBL] [Abstract][Full Text] [Related]
15. Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders.
Furlotti G; Alisi MA; Cazzolla N; Dragone P; Durando L; Magarò G; Mancini F; Mangano G; Ombrato R; Vitiello M; Armirotti A; Capurro V; Lanfranco M; Ottonello G; Summa M; Reggiani A
J Med Chem; 2015 Nov; 58(22):8920-37. PubMed ID: 26486317
[TBL] [Abstract][Full Text] [Related]
16. The Wnt signaling pathway in bipolar disorder.
Gould TD; Manji HK
Neuroscientist; 2002 Oct; 8(5):497-511. PubMed ID: 12374432
[TBL] [Abstract][Full Text] [Related]
17. Glycogen synthase kinase-3β activity and cognitive functioning in patients with bipolar I disorder.
Munkholm K; Miskowiak KW; Jacoby AS; Vinberg M; Leme Talib L; Gattaz WF; Kessing LV
Eur Neuropsychopharmacol; 2018 Mar; 28(3):361-368. PubMed ID: 29433844
[TBL] [Abstract][Full Text] [Related]
18. Glycogen synthase kinase 3β gene polymorphisms may be associated with bipolar I disorder and the therapeutic response to lithium.
Lin YF; Huang MC; Liu HC
J Affect Disord; 2013 May; 147(1-3):401-6. PubMed ID: 23021822
[TBL] [Abstract][Full Text] [Related]
19. Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors.
Gould TD; Einat H; O'Donnell KC; Picchini AM; Schloesser RJ; Manji HK
Neuropsychopharmacology; 2007 Oct; 32(10):2173-83. PubMed ID: 17299510
[TBL] [Abstract][Full Text] [Related]
20. A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors.
Du J; Wei Y; Liu L; Wang Y; Khairova R; Blumenthal R; Tragon T; Hunsberger JG; Machado-Vieira R; Drevets W; Wang YT; Manji HK
Proc Natl Acad Sci U S A; 2010 Jun; 107(25):11573-8. PubMed ID: 20534517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
